linjc16/ctgov huggingface dataset:
The Effect of a Very Low-residual Diet on the Preparation Before Capsule Endoscopy

Study Overview
=================
Brief Summary
-----------------
The aim of the proposed study is to compare prospectively two methods of small bowel preparation prior capsule endoscopy study, the effect on the cleanliness and the quality of visualization after two protocols of preparation: a 12 hour fast only versus 24 hour of a very low residual diet (ENSURE, Abbott Laboratories, Israel) + 12 hour fast.

Conditions
-----------------
Gastrointestinal Complaints

Intervention / Treatment
-----------------
* Dietary Supplement: 24-hour low-residual diet


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Consecutive patients who will submitted to capsule endoscopy due to following medical indications: suspected Crohn's disease obscure GI bleeding iron deficiency anemia suspected malabsorption disease unexplained abdominal pain unexplained chronic diarrhea Exclusion Criteria: pregnancy patients who had previous surgery on Gastrointestinal tract patients with previous intestinal obstruction patients who will refuse to participate in the study diabetes mellitus known celiac disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: 12-hour fast<br> | |
| Active Comparator: 24-hour low-residual diet and 12-hour fast<br> | Dietary Supplement: 24-hour low-residual diet<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cleanliness and better visualization of the small bowel during capsule endoscopy |  | 2 years |
Evaluation of Clinical Outcomes in an Online Teledermatology Model for the Management of Psoriasis

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine if an asynchronous online model of teledermatology can achieve similar clinical outcomes as compared to conventional in-office care for the management of psoriasis. The investigators also aim to determine the effects of this online care model on patient quality of life as well as patient and physician satisfaction. The investigators' hypotheses include the following: Compared to in-person visits, the online care model will result in similar clinical improvement in psoriasis disease severity. Compared to in-person visits, the online care model will result in similar improvements in quality of life. Providers and subjects in the online group will achieve a similar level of overall satisfaction as those in the in-person group.

Official Title
-----------------
Evaluation of Clinical Outcomes in an Online Teledermatology Model for the Management of Psoriasis

Conditions
-----------------
Psoriasis

Intervention / Treatment
-----------------
* Other: Online Teledermatology Care
* Other: Conventional in Office Care


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 years of age or older at time of consent, may be men or women. Requiring treatment of psoriasis for medically-indicated reasons. Capable of giving informed consent. Able to have their skin imaged by themselves or by family members. Exclusion Criteria: Non-English speaking individuals. Individuals lacking access to a digital camera and computer with internet connection.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Teledermatology<br>Online Telemedicine Group | Other: Online Teledermatology Care<br>* Patients randomized to the intervention group will have their scheduled follow-up visits online via a store and forward teledermatology modality.<br>* Other names: Health care service modality;|
| Active Comparator: Usual Care<br>Conventional in-office care | Other: Conventional in Office Care<br>* Patients randomized to the control group will have their scheduled follow-up visits via conventional in office care.<br>* Other names: Health care service modality;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Psoriasis Area Severity Index (PASI) |  | Every 6-8 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Teledermatology, Telemedicine, Psoriasis
Cryoprobe Transbronchial Lung Biospy in Patients With Mechanical Ventilation

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the the diagnostic yield and safety of transbronchial lung biopsies (TBLB) with cryoprobe in patients with mechanical ventilation.

Conditions
-----------------
Lung Diseases, Interstitial Disease

Intervention / Treatment
-----------------
* Procedure: Cryoprobe


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ≥18 years old Patients with mechanical ventilation. Patients with diffuse lung disease of unknown etiology. Need for confirming/excluding a diagnosis, with therapeutical and prognosis implications. Inform consent signed by family. Exclusion Criteria: Use of anticoagulant therapy or presence of a coagulation disorder (abnormal platelets counts, international normalized ratio > 1.5). Comorbidities that could increase the risk of the TBLB. Bullous emphysema. Hemoptysis, pneumothorax. Severe respiratory insufficiency requiring PEEP >12 cm H2O

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Transbronchial lung biopsy with cryoprobe<br> | Procedure: Cryoprobe<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adverse events related to transbronchial lung biopsy (TBLB) with cryoprobe |  | 27 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Diagnostic yield of transbronchial lung biopsy (TBLB) obtained by cryoprobes |  | 27 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cryoprobes, Cryobiopsy, Transbronchial lung biopsy
Ultrasound Guidance for Epidural Analgesia and Anesthesia

Study Overview
=================
Brief Summary
-----------------
Most women delivering by cesarean at BC Women's receive regional anesthesia; which includes spinal, epidural, or combined spinal-epidural anesthesia. In all these techniques a needle is placed in the lower back and local anesthetic is injected to freeze the body. Normally, before the needle is placed in a patients' back, the anesthesiologist will feel between their back bones with his/her fingers to find the right spot for the needle. This study will be evaluating if the distance from the skin to the appropriate spinal space measured with a novel 3D Ultrasound will equal the actual depth of the needle insertion.

Detailed Description
-----------------
The investigators will be evaluating if the distance from the skin to the appropriate spinal space measured with a novel 3D Ultrasound will equal the actual depth of the needle insertion.

Official Title
-----------------
Ultrasound Guidance for Epidural Analgesia and Anesthesia

Conditions
-----------------
Epidural Space Depth

Intervention / Treatment
-----------------
* Device: Ultrasound


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: term pregnancy elective cesarean Exclusion Criteria: scoliosis high bmi

Ages Eligible for Study
-----------------
Minimum Age: 19 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| study group<br>elective cesarean delivery patients | Device: Ultrasound<br>* Parturients backs will be scanned using 3D ultrasound to measure the depth to the epidural space<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| epidural space depth | comparison of ultrasound measured epidural space to actual needle insertion | intraoperative |
Yunzhi as Dietary Supplement in Breast Cancer

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assess the effects of a dietary supplement, the traditional Asian mushroom Yunzhi, as adjuvant in the treatment of patients with breast cancer.

Official Title
-----------------
A Randomized, Parallel, Double-blind, Placebo-controlled, Pilot Clinical Study on the Effects of Yunzhi as Dietary Supplement in 60 Adult Patients Undergoing Adjuvant/Neoadjuvant Chemotherapy for Breast Cancer.

Conditions
-----------------
Breast Cancer

Intervention / Treatment
-----------------
* Dietary Supplement: Yunzhi extract
* Dietary Supplement: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women with diagnosis of breast cancer Undergoing adjuvant/neoadjuvant chemotherapy with either FEC, FAC, TAC, or EC + docetaxel combinations. ≥ 18 years of age Performance status: 0-2 Ability to provide written informed consent Exclusion Criteria: Any prior history of yunzhi use Use of other herbal remedies during the study duration Significant cardiac, pulmonary, renal, hepatic, gastrointestinal, CNS, psychiatric disease or illicit substance use/abuse that in the opinion of the investigator would make the participant a poor candidate for study participation Pregnancy (for women of childbearing potential, a negative pregnancy test, urine or serum, is required within 14 days prior to randomization) Systemic use of progestins, androgens or other steroids (dexamethasone is allowed if used as antiemetic therapy)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>Yunzhi extract 3.5 g/day | Dietary Supplement: Yunzhi extract<br>* 3.5 g/day<br>|
| Placebo Comparator: 2<br>Placebo | Dietary Supplement: Placebo<br>* Placebo (starch)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mean change in signs and symptoms from baseline measured by Visual Analogue Scale (VAS) |  | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Treatment adherence Clinical and laboratory (including RBC, WBC and platelets) adverse events Adherence to chemotherapy schedule EPO and blood transfusion needs |  | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Breast cancer, undergoing, adjuvant/neoadjuvant chemotherapy, symptomatic therapy
fMRI Study of Grasping in Autistic Patients

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to localise brain regions involved in objects recognition, in planification and adjustment of grasping, in prehension with and without eye control. The study is conducted in normal and autistic adults. We hypothesize different activations in these two populations.

Official Title
-----------------
fMRI Study of Grasping in Autistic Patients

Conditions
-----------------
Autistic Disorder

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: clinical diagnosis of autistic disorder, right-handed, DQ>50 Exclusion Criteria: epilepsia, psychotropic drugs

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
TIPS With 8- OR 10-mm Covered Stent for Preventing Variceal Rebleeding

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether transjugular intrahepatic portosystemic shunt (TIPS) with 10-mm covered stent is associated with lower shunt dysfunction in comparing TIPS with 8-mm covered stent in cirrhotic patients with at least one episode of variceal bleeding.

Official Title
-----------------
The Effect of TIPS With 8- or 10-mm Covered Stent for Preventing Variceal Rebleeding in Cirrhotic Patients.

Conditions
-----------------
Decompensated Cirrhosis, Portal Hypertension, Bleeding Varices

Intervention / Treatment
-----------------
* Device: 8-mm covered stent group
* Device: 10-mm covered stent group


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Cirrhotic patients with at least one episode of variceal bleeding No active bleeding within 5 days before TIPS Child-Pugh score ≤13 Signed written informed consent Exclusion Criteria: An age <18 years or >75 years With TIPS contraindications Past or present history of hepatic encephalopathy Pregnancy or breast-feeding Hepatic carcinoma and/or other malignancy diseases Sepsis Spontaneous bacterial peritonitis Uncontrollable hypertension Serious cardiac or pulmonary dysfunction Renal failure Portal vein thrombosis History of organ transplantation History of HIV (human immunodeficiency viruses) infection

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 10-mm covered stent group<br>Patients treated with 10-mm covered stent. | Device: 10-mm covered stent group<br>* Creating a shunt between hepatic vein and portal vein with a 10-mm covered stent by TIPS procedure.<br>|
| Active Comparator: 8-mm covered stent group<br>Patients treated with 8-mm covered stent. | Device: 8-mm covered stent group<br>* Creating a shunt between hepatic vein and portal vein with a 8-mm covered stent by TIPS procedure.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of shunt dysfunction. |  | 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of variceal rebleeding |  | 2 years | 
| Incidence of hepatic encephalopathy |  | 2 years | 
| Survival |  | 2 years | 
| Incidence of hepatic myelopathy |  | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
transjugular intrahepatic portosystemic shunt, TIPS, liver cirrhosis, variceal bleeding, 8- or 10-mm covered stent
RFN-Advanced Retrograde Femoral Nailing System

Study Overview
=================
Brief Summary
-----------------
This study is a retrospective chart review of the safety and performance Standard of Care data on individuals that have previously been implanted with the femur nail of the RFNA System for the internal fixation of the femur. Demographics, medical history, primary diagnosis, mechanism of injury, type of injury, clinical and radiographic evaluation of bone consolidation, and device-related adverse events were collected. Descriptive statistics were applied to the data collected.

Official Title
-----------------
RFN-Advanced Retrograde Femoral Nailing System (RFNA) - Early Usage Case-Series Utilizing the Retrograde Femoral Nail-Advanced for Fixation and Stabilization of the Distal Femur and Femoral Shaft

Conditions
-----------------
Femur Fracture

Intervention / Treatment
-----------------
* Device: Depuy Synthes Advanced Retrograde femoral nail


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects 18 years or older at the time of index procedure Subjects who received the Depuy Synthes Advanced Retrograde Nail in accordance with the indications for use. Subjects who have at least 6 months of follow-up. Exclusion Criteria: Subject with less than 6 months of follow up, pathologic fractures, and patients < 18 years of age will be excluded from the study.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Control<br>Historical patient data from other published studies in the literature | |
| Study participants<br>Adult patients with non-pathologic distal femur and femoral shaft fractures treated with the Depuy Synthes Advanced Retrograde femoral nail who had at least 6 months of follow up. | Device: Depuy Synthes Advanced Retrograde femoral nail<br>* The Advanced Retrograde Femoral Nailing System (RFNA) is designed to improve fixation and stabilization of distal femur and femoral shaft fractures by reducing toggle and loss of reduction.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Union | Rate of fracture union | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Infection | Rate of infection | 6 months | 
| Implant breakage | Rate of implant breakage | 6 months | 
| Implant removal | Rate of symptomatic implant removal | 6 months | 
| Malunion | Rate of malunion | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Retrograde, Intramedullary Nail, Union
A Comparative Study of the Air-Q ILA and the ILMA for Ventilation and Intubation

Study Overview
=================
Brief Summary
-----------------
The objective of this study is to determine if the glottic view obtained with the air-Q Intubating Laryngeal Airway (air-Q ILA, Cookgas LLC®, Mercury Medical®, Clearwater, FL, USA) is better than that obtained with the traditionally used intubating laryngeal mask airway (LMA FastrachTM or ILMA, LMA North America Inc., San Diego, CA). The study will also compare effectiveness of ventilation.

Conditions
-----------------
Airway Management

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: healthy ASA class I and II patients scheduled for elective surgery under general anesthesia requiring the use of the LMA Exclusion Criteria: history of acid reflux, a BMI ≥ 40kg.m-2, require endotracheal intubation, have predictors of difficult intubation, not candidates for insertion of an ILMA or LMA, including a mouth opening of less than 2.5 cm, cannot consent to the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| air-Q Intubating Laryngeal Airway<br> | |
| LMA FastrachTM or ILMA<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |